Status: Not yet recruiting
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
The purpose of this study is to determine the safety, tolerability, PK and pharmacodynamics of KK2223 in adult participants with relapsed or refractory peripheral T cell lymphoma (PTCL) or cutaneous T cell lymphoma (CTCL).
Participants needed: 72
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Kyowa Kirin, Inc.Updated: Jul 1, 2026Locations: 17
Eligibility criteria
Adults (≥18 years) with confirmed T-cell lymphoma subtypes: PTCL (including noda... [+9]
Recent autologous or allogeneic transplant within 120 days before treatment; act... [+15]